Envestnet Asset Management Inc. Has $90.85 Million Position in Agilent Technologies, Inc. (NYSE:A)

Envestnet Asset Management Inc. lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 9.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 676,275 shares of the medical research company’s stock after selling 73,292 shares during the period. Envestnet Asset Management Inc. owned about 0.24% of Agilent Technologies worth $90,851,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. CKW Financial Group boosted its stake in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after buying an additional 100 shares during the period. Global X Japan Co. Ltd. raised its holdings in shares of Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in Agilent Technologies in the fourth quarter valued at about $29,000. Hanson & Doremus Investment Management lifted its stake in Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 105 shares during the last quarter. Finally, OFI Invest Asset Management acquired a new stake in Agilent Technologies in the 4th quarter worth approximately $37,000. 87.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on A. Citigroup upped their target price on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. Barclays raised Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Bank of America lowered their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Robert W. Baird cut their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $150.83.

Agilent Technologies Trading Down 4.5 %

Shares of NYSE A opened at $98.97 on Wednesday. Agilent Technologies, Inc. has a 1-year low of $97.37 and a 1-year high of $155.35. The company has a 50-day moving average of $127.40 and a two-hundred day moving average of $134.90. The company has a market cap of $28.22 billion, a PE ratio of 22.75, a P/E/G ratio of 2.91 and a beta of 1.19. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 1.00%. Agilent Technologies’s payout ratio is 22.76%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel K. Podolsky sold 1,819 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now owns 35,737 shares of the company’s stock, valued at $4,161,931.02. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,638 shares of company stock valued at $731,229. 0.26% of the stock is currently owned by insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.